Javascript must be enabled to continue!
TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding
View through CrossRef
Abstract
c-Myc
protooncogene places a demand on glucose uptake to drive glucose-dependent biosynthetic pathways. To achieve this demand, c-Myc protein (Myc henceforth) drives the expression of glucose transporters and represses the expression of Thioredoxin Interacting Protein (TXNIP), which is a potent negative regulator of glucose uptake. A Myc
high
/TXNIP
low
gene signature is clinically significant as it correlates with poor clinical prognosis in Triple-Negative Breast Cancer (TNBC) but not in other subtypes of breast cancer. To better understand how TXNIP function contributes to the aggressive behavior of TNBC, we generated TXNIP null MDA-MB-231 (231:TKO) cells for our study. We show here that TXNIP loss drives a transcriptional program that resembles those driven by Myc and increases global Myc genome occupancy. TXNIP loss allows Myc to invade the promoters and enhancers of target genes that are potentially relevant to cell transformation. Together, these findings suggest that TXNIP is a broad repressor of Myc genomic binding. The increase in Myc genomic binding in the 231:TKO cells expands the Myc-dependent transcriptome we identified in parental MDA-MB-231 cells. This expansion of Myc-dependent transcription following TXNIP loss occurs without an apparent increase in Myc’s intrinsic capacity to activate transcription and without increasing Myc levels. Together, our findings suggest that TXNIP loss mimics Myc overexpression, connecting Myc genomic binding and transcriptional programs to the metabolic signals that control TXNIP expression.
Title: TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding
Description:
Abstract
c-Myc
protooncogene places a demand on glucose uptake to drive glucose-dependent biosynthetic pathways.
To achieve this demand, c-Myc protein (Myc henceforth) drives the expression of glucose transporters and represses the expression of Thioredoxin Interacting Protein (TXNIP), which is a potent negative regulator of glucose uptake.
A Myc
high
/TXNIP
low
gene signature is clinically significant as it correlates with poor clinical prognosis in Triple-Negative Breast Cancer (TNBC) but not in other subtypes of breast cancer.
To better understand how TXNIP function contributes to the aggressive behavior of TNBC, we generated TXNIP null MDA-MB-231 (231:TKO) cells for our study.
We show here that TXNIP loss drives a transcriptional program that resembles those driven by Myc and increases global Myc genome occupancy.
TXNIP loss allows Myc to invade the promoters and enhancers of target genes that are potentially relevant to cell transformation.
Together, these findings suggest that TXNIP is a broad repressor of Myc genomic binding.
The increase in Myc genomic binding in the 231:TKO cells expands the Myc-dependent transcriptome we identified in parental MDA-MB-231 cells.
This expansion of Myc-dependent transcription following TXNIP loss occurs without an apparent increase in Myc’s intrinsic capacity to activate transcription and without increasing Myc levels.
Together, our findings suggest that TXNIP loss mimics Myc overexpression, connecting Myc genomic binding and transcriptional programs to the metabolic signals that control TXNIP expression.
Related Results
Molecular mechanisms of cellular control through the TXNIP protein
Molecular mechanisms of cellular control through the TXNIP protein
<p dir="ltr">The thioredoxin-interacting protein (TXNIP) is a unique member of the a-arrestin family, as it is the only arrestin identified as an endogenous inhibitor of thio...
Molecular mechanisms of cellular control through the TXNIP protein
Molecular mechanisms of cellular control through the TXNIP protein
<p dir="ltr">The thioredoxin-interacting protein (TXNIP) is a unique member of the a-arrestin family, as it is the only arrestin identified as an endogenous inhibitor of thio...
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract
Small cell lung cancer and large cell neuroendocrine carcinoma are classified as high-grade neuroendocrine tumors of the lung, representing extremely agg...
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Smooth Muscle Cell-Specific Txnip Deficiency Ameliorates Vascular Calcification
Smooth Muscle Cell-Specific Txnip Deficiency Ameliorates Vascular Calcification
Vascular calcification is a significant pathological characteristic of cardiovascular diseases, often exacerbated by metabolic disorders such as chronic kidney disease and diabetes...
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Abstract
Background and significance. Stemness in acute myeloid leukemia (AML) is determined by a clonal hierarchy with ...
Overview on Thioredoxin-Interacting Protein (TXNIP): A Potential
Target for Diabetes Intervention
Overview on Thioredoxin-Interacting Protein (TXNIP): A Potential
Target for Diabetes Intervention
Background:
Diabetes mellitus (DM) is a common metabolic disorder characterized by a persistent increment of blood glucose. Type 2 DM is characterized by insulin resistance and β-c...

